Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.

Onuma Y, Miquel-Hebert K, Serruys PW; SPIRIT II Investigators.

EuroIntervention. 2013 Jan 22;8(9):1047-51. doi: 10.4244/EIJV8I9A161.

PMID:
23339811
[PubMed - indexed for MEDLINE]
Free Article
2.

Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.

Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K.

Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550. Review.

PMID:
19952925
[PubMed - indexed for MEDLINE]
3.

Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher).

Biondi-Zoccai G, Lotrionte M, Moretti C, Agostoni P, Sillano D, Laudito A, Sheiban I.

Minerva Cardioangiol. 2008 Feb;56(1):55-65. Review.

PMID:
18432169
[PubMed - indexed for MEDLINE]
4.

The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions.

Waugh J, Wagstaff AJ.

Am J Cardiovasc Drugs. 2004;4(4):257-68. Review.

PMID:
15285700
[PubMed - indexed for MEDLINE]
5.

Newly available and recent advances in drug-eluting stents.

Costopoulos C, Latib A, Naganuma T, Sticchi A, Giannini F, Colombo A.

Expert Rev Cardiovasc Ther. 2013 May;11(5):555-66. doi: 10.1586/erc.13.43. Review.

PMID:
23621138
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk